Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | FNTA | P49354 | 5/20 | 0.55 |
| ▸ | FNTB | P49356 | 4/20 | 0.55 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29165442 | 1.00 | ALDH1A1 (0.67) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL18604017 | 0.98 | ALDH1A1 (0.69) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL5596597 | 0.98 | ALDH1A1 (0.69) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL1793466 | 0.98 | ALDH1A1 (0.69) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL874195 | 0.98 | ALDH1A1 (0.69) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL874196 | 0.98 | ALDH1A1 (0.69) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL30136431 | 0.90 | ALDH1A1 (0.55) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL29142859 | 0.90 | ALDH1A1 (0.76) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL4955238 | 0.89 | ALDH1A1 (0.51) | ALDH1A1ALOX15FNTAFNTBPGGT1B | |
| SCHEMBL8662149 | 0.88 | ALDH1A1 (0.79) | ALDH1A1ALOX15FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176311-A1 | Composition and method for treating cancer | MO HUANBIAO (US) | 2004-09-09 | — | — | US | claimed |
| EP-1061907-A1 | MONOTERPENOID DERIVATIVES FOR TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-12-27 | — | — | EP | claimed |
| WO-1999045912-A1 | MONOTERPENOID DERIVATIVES FOR TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-09-16 | — | — | WO | claimed |
| US-7074825-B2 | Composition and method for treating cancer | MO HUANBIAO | 2006-07-11 | — | — | US | disclosed |
| US-6911318-B2 | Bacterial transglycosylases: assays for monitoring the activity using Lipid II substrate analogs and methods for discovering new antibiotics | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20040176311-A1 | Composition and method for treating cancer | MO HUANBIAO (US) | 2004-09-09 | — | — | US | disclosed |
| US-20030129683-A1 | Bacterial transglycosylases: assays for monitoring the activity using Lipid II substrate analogs and methods for discovering new antibiotics | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2003-07-10 | — | — | US | disclosed |
| US-6566397-B2 | Acyclic isoprenoid ether derivatives as chemotherapeutics | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-05-20 | — | — | US | disclosed |
| US-6461829-B1 | DRUG SCREENING ENZYME INHIBITORS | THE TRUSTEES OF PRINCETON UNIVERSITY | 2002-10-08 | — | — | US | disclosed |
| US-20020045584-A1 | Acyclic isoprenoid ether derivatives as chemotherapeutics | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2002-04-18 | — | — | US | disclosed |
| WO-2002005856-A2 | ACYCLIC ISOPRENOID ETHER DERIVATIVES AS CHEMOTHERAPUETICS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-1159293-A1 | BACTERIAL TRANSGLYCOSYLASES: ASSAYS FOR MONITORING THE ACTIVITY USING LIPID II SUBSTRATE ANALOGS AND METHODS FOR DISCOVERING NEW ANTIBIOTICS | PRINCETON UNIVERSITY (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6303654-B1 | EXPOSING TUMOR CELLS TO FARNESYL ANTHRANILATE AND CARRIER TO INHIBIT OR REDUCE TUMOR CELL GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2001-10-16 | — | — | US | disclosed |
| US-6303654-B1 | EXPOSING TUMOR CELLS TO FARNESYL ANTHRANILATE AND CARRIER TO INHIBIT OR REDUCE TUMOR CELL GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2001-10-16 | — | — | US | disclosed |
| EP-1061907-A1 | MONOTERPENOID DERIVATIVES FOR TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-1061907-A1 | MONOTERPENOID DERIVATIVES FOR TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-2000052035-A1 | BACTERIAL TRANSGLYCOSYLASES: ASSAYS FOR MONITORING THE ACTIVITY USING LIPID II SUBSTRATE ANALOGS AND METHODS FOR DISCOVERING NEW ANTIBIOTICS | PRINCETON UNIVERSITY (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999045912-A1 | MONOTERPENOID DERIVATIVES FOR TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999045912-A1 | MONOTERPENOID DERIVATIVES FOR TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129683-A1 | Bacterial transglycosylases: assays for monitoring the activity using Lipid II substrate analogs and methods for discovering new antibiotics | COASY, PGLS, MGAM | ALDH1A1 2138/4885ALOX15 882/4885FNTA 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.